Department of Reproductive Medicine and Fertility Preservation, Antoine Béclère Hospital, APHP, Paris-Saclay University, 92140, Clamart, France.
Reproductive Biology Unit CECOS, Antoine Béclère Hospital, AP-HP, Paris Saclay University, 92140, Clamart, France.
J Assist Reprod Genet. 2023 Mar;40(3):473-480. doi: 10.1007/s10815-023-02739-6. Epub 2023 Feb 8.
The objective of the present study was to evaluate whether oocyte vitrification following controlled ovarian stimulation (COS) for fertility preservation (FP) delays the initiation of neoadjuvant chemotherapy (NAC) for breast cancer (BC) as compared to in vitro maturation (IVM).
We performed a retrospective cohort study including all BC patients eligible for oocyte vitrification following COS or in vitro maturation (IVM) before initiation of NAC between January 2016 and December 2020. The inclusion criteria were female patients aged between 18 and 40, with confirmed non metastatic BC, with indication of NAC, who have had oocyte retrieval for FP after COS, or IVM + / - cryopreservation of ovarian tissue (OTC). Various time points related to cancer diagnosis, FP, or chemotherapy were obtained from a medical record review.
A total of 197 patients with confirmed BC who had oocyte retrieval following COS (n = 57) or IVM + / - OTC (n = 140) for FP prior to NAC were included. Overall, the average time from cancer diagnosis to chemotherapy start was similar between patients having undergone COS or IVM before oocyte vitrification (37.3 ± 13.8 vs. 36. 8 ± 13.5 days; p = 0.89).
The indication of NAC for BC should not be considered as an impediment to urgent COS for oocyte vitrification for FP.
本研究旨在评估与体外成熟（IVM）相比，控制性卵巢刺激（COS）用于生育力保存（FP）后卵母细胞玻璃化是否会延迟乳腺癌（BC）新辅助化疗（NAC）的开始。
我们进行了一项回顾性队列研究，纳入了 2016 年 1 月至 2020 年 12 月期间所有在开始 NAC 前因 BC 有进行 COS 或 IVM 以进行卵母细胞冷冻保存（FP）的适应证的女性患者。纳入标准为年龄在 18 至 40 岁之间、确诊为非转移性 BC、有 NAC 适应证、进行过 COS 以进行 FP 后卵母细胞采集或 IVM + / - 卵巢组织冷冻保存（OTC）的患者。从病历回顾中获取与癌症诊断、FP 或化疗相关的各种时间点。
共纳入 197 例在开始 NAC 前因 FP 进行 COS（n = 57）或 IVM + / - OTC（n = 140）以进行卵母细胞冷冻保存的确诊 BC 患者。总体而言，在进行 COS 或 IVM 以进行卵母细胞玻璃化之前，从癌症诊断到开始化疗的平均时间相似（37.3 ± 13.8 与 36.8 ± 13.5 天；p = 0.89）。
不应将 BC 的 NAC 适应证视为进行紧急 COS 以进行 FP 卵母细胞玻璃化的障碍。
